Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer

Peter Kulesza, Kavitha Ramchandran, Jyoti D. Patel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Non-small cell lung cancer (NSCLC) is traditionally classified histologically, but until recently, the histologic subtype has had little impact on the selection of therapy. Drugs such as pemetrexed and bevacizumab are indicated for specific NSCLC subtypes, and this type of stratification represents the first step toward individualizing therapy in NSCLC. Beyond histologic features, the status of molecular targets, such as the epidermal growth factor receptor (EGFR) gene, has been shown to correlate with response to treatment with EGFR tyrosine kinase inhibitors in patients with relapsed or refractory disease and in the first-line therapy setting. New therapies targeting the EGFR and other molecular aberrations are under way to help define specific subsets of patients responsive to certain molecularly targeted treatments. The role of pathologists in guiding treatment decisions will increase because molecular profiling, together with pathologic and histologic analysis, represents the future of personalizing medicine for patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)228-238
Number of pages11
JournalAmerican journal of clinical pathology
Issue number2
StatePublished - Aug 2011


  • Afatinib (BIBW 2992)
  • Epidermal growth factor receptor
  • Erlotinib
  • Gefitinib
  • Non-small cell lung cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this